Vertex Pharmaceuticals (MEX:VRTX) Cyclically Adjusted Revenue per Share: MXN547.14 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:VRTX Vertex Pharmaceuticals Inc MEX:VRTX
91 GF Score
Price MXN8,319.00
GF Value MXN8,809.34
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share?

Vertex Pharmaceuticals MEX:VRTX -1.83% 91 Cyclically Adjusted Revenue per Share is MXN547.14 as of Mar. 2026. GuruFocus rates MEX:VRTX with a GF Score™ of 91/100 and a GF Value™ of MXN8,809.34 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was MXN210.152. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN547.14 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 21.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 24.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 25.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vertex Pharmaceuticals was 29.90% per year. The lowest was -4.70% per year. And the median was 16.05% per year.

As of today (2026-07-16), Vertex Pharmaceuticals's current stock price is MXN8319.00. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN547.14. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 15.20.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 37.95. The lowest was 13.63. And the median was 21.25.


Vertex Pharmaceuticals  (MEX:VRTX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=8319.00/547.14
=15.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 37.95. The lowest was 13.63. And the median was 21.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 267.82 313.12 333.88 504.20 528.19

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 532.84 503.62 501.18 528.19 547.14

MEX:VRTX vs REGN, ALNY, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


MEX:VRTX
91GF Score
Vertex Pharmaceuticals Inc MEX:VRTX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=210.152/330.2130*330.2130
=210.152

Current CPI (Mar. 2026) = 330.2130.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 32.648 241.018 44.730
201609 32.667 241.428 44.680
201612 38.576 241.432 52.761
201703 54.111 243.801 73.290
201706 39.088 244.955 52.693
201709 41.925 246.819 56.090
201712 49.871 246.524 66.801
201803 45.031 249.554 59.586
201806 57.156 251.989 74.899
201809 56.487 252.439 73.890
201812 65.754 251.233 86.425
201903 64.003 254.202 83.141
201906 69.591 256.143 89.715
201909 71.990 256.759 92.585
201912 101.633 256.974 130.599
202003 134.817 258.115 172.475
202006 133.591 257.797 171.117
202009 128.681 260.280 163.255
202012 123.824 260.474 156.976
202103 134.580 264.877 167.776
202106 136.779 271.696 166.238
202109 157.093 274.310 189.108
202112 165.501 278.802 196.019
202203 161.936 287.504 185.992
202206 170.789 296.311 190.330
202209 180.942 296.808 201.307
202212 172.468 296.797 191.886
202303 164.448 301.836 179.909
202306 164.144 305.109 177.650
202309 166.001 307.789 178.095
202312 163.865 306.746 176.401
202403 171.022 312.332 180.813
202406 187.786 314.175 197.372
202409 209.117 315.301 219.007
202412 236.035 315.605 246.960
202503 218.394 319.799 225.506
202506 215.616 322.561 220.731
202509 219.076 324.800 222.727
202512 224.193 324.054 228.454
202603 210.152 330.213 210.152

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN547.14 mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Cyclically Adjusted Revenue per Share of MXN547.14 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Vertex Pharmaceuticals' current Cyclically Adjusted Revenue per Share is MXN547.14. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to REGN and ALNY?
Vertex Pharmaceuticals' Cyclically Adjusted Revenue per Share of MXN547.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cyclically Adjusted Revenue per Share is MXN547.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,809.34, compared to a current price of MXN8,319.00 — trading 5.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN547.14. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Cyclically Adjusted Revenue per Share is MXN547.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of MXN8,319.00 is trading 5.6% below its estimated GF Value™ of MXN8,809.34. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:VRTX:

  • Cyclically Adjusted Revenue per Share: MXN547.14
  • GF Value™: MXN8,809.34 vs. price of MXN8,319.00 (5.6% below fair value)
  • GF Score™: 91/100 with 5 warning signs

No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score

Get the complete analysis for MEX:VRTX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN8,319.00
Price
MXN8,809.34
GF Value